Integrin-mediated leukocyte interactions: Regulation by haemostatic factors

Hamostaseologie

Volumn 25, Issue 1, 2005, Pages 33-38

  Chavakis, T ^a   Preissner, K T ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Haemostasis; Inflammation; Integrin

Indexed keywords

ANGIOSTATIN; HEMOSTATIC AGENT; HIGH MOLECULAR WEIGHT KININOGEN; INTEGRIN; PLASMINOGEN; UROKINASE; UROKINASE RECEPTOR;

CONFERENCE PAPER; DRUG MECHANISM; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; NONHUMAN; REGULATORY MECHANISM; VASCULAR DISEASE;

EID: 14244252786     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619645     Document Type: Conference Paper

References (68)

1. Albrecht S, Magdolen V, Herzog U et al. Soluble tissue actor interferes with angiostatin-mediated inhibition of endothelial cell proliferation by lysine-specific interaction with plasminogen kringle domains. Thromb Haemost 2002; 88: 1054-9.
2. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Ann Rev Med 1987; 38: 175-94.
3. Andreasen PA, Egelund R, Petersen HH, The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57, 25-40.
4. Behrendt N, Stephens RW. (Titel??) Fibrinol Proteol 1998; 12: 191-204.
5. Benelli R, Morini M, Carrozzino F et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002; 16: 267-9.
6. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
7. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorpho-nuclear leukocyte. Blood. 1997; 89: 3503-21.
8. Bradford HN, DeLa Cadena RA, Kunapuli SP et al. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood 1997; 90: 1508-15.
9. Buschmann I, Heil M, Jost M et al. Influence of inflammatory cytokines on arteriogenesis. Microcirculation 2003; 10: 371-9.
10. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol 1999; 73; 369-509. ( Seitenzahlen?)
11. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-101.
12. Chavakis T, Preissner KT, Santoso S. Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thromb Haemost 2003; 89: 13-7.
13. Chavakis T, Kanse SM, May AE et al. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem Soc Trans 2002; 30: 168-73.
14. Chavakis T, May AE, Preissner KT et al. Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins. Blood 1999; 93: 2976-83.
15. Chavakis T, Athanasopoulos A, Rhee JS et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood 2004; (Epub ahead of print)
16. Chavakis T, Kanse SM, Lupu F et al. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 2000; 96: 514-22.
17. Chavakis T, Kanse SM, Pixley M et al. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J 2001; 15: 2365-76.
18. Chavakis T, Santoso S, Clemetson KJ et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 2003; 278: 45375-81.
19. Chavakis T, Preissner KT. Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen. Curr Vasc Pharmacol 2003; 1: 59-64.
20. Chavakis T, Boeckel N, Santoso S et al. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen. J Biol Chem 2002; 277: 23157-64.
21. Chavakis T, Pixley RA, Isordia-Salas I et al. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J Biol Chem 2002; 277: 32677-82.
22. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
23. Colman RW, Pixley RA, Najamunnisa S et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-7.
24. Diacovo TG, de Fougerolles AR, Bainton DF et al. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 1994; 94: 1243-51.
25. Ebnet K, Suzuki A, Ohno S et al. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci 2004; 117; 19-29.
26. Etzioni A, Doerschuk CM, Harlan JM. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood 1999; 94: 3281-8.
27. Feng D, Nagy JA, Pyne K et al. Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med 1998; 187: 903-15.
28. Gahmberg CG. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Cun Opin Cell Biol 1997; 9: 643-50.
29. Harder T, Simons K. Caveolae. DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 1997; 9: 534-42.
30. Kasan AAK, Cines DB, Herwald H et al. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem 1995; 270: 19256-61.
31. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 1998; 95: 3615-20.
32. Herwald H, Dedio J, Kellner R et al. Isolation and characterization of the kininogenbinding protein p33 from endothelial cells:Identity with the gClq receptor. J Biol Chem 1996; 271: 13040-7.
33. Herwald H, Hasan AAK, GodovacZimmermann J et al. Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem 1995; 270: 14634-42.
34. Horejsi V, Drbal K, Cebecauer M et al. GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today 1999; 20: 356-61.
35. Liao F, Ali J, Greene T et al. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med 1997; 185: 1349-57.
36. Lin Y, Harris RB, Yan W et al. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997; 90: 690-7.
37. Lishko VK, Novokhatny VV, Yakubenko VP et al. Characterization of plasminogen as an adhesive ligand for integrins alphaMbeta2 (Mac-1) and alpha5beta1 (VLA-5). Blood 2004; 104: 719-26.
38. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11: 428-42.
39. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994; 31: 261-9.
40. May AE, Kanse SM, Lund LR et al. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998; 188: 1029-37.
41. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-56.
42. Milne DB, Ralston NV, Wallwork JC. Zinc content of cellular components of blood: methods for cell separation and analysis evaluated. Clin Chem 1985; 31: 65-9.
43. Moulton KS, Vakili K, Zurakowski D et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci. USA 2003; 100: 4736-41.
44. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82: 521-33.
45. O'Reilly MS, Holmgren L, Chen C et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
46. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
47. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 613-20.
48. Petty HR, Todd RF. Integrins as promiscuous signal transduction devices. Immunol Today 1996; 17: 209-12.
49. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin aMβ2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 2003; 101: 1582-90.
50. Pluskota E, Soloviev DA, Bdeir K et al. Integrin aMβ2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 18063-72.
51. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.
52. Rebuck JW. The skin window as a monitor of leukocytic functions in contact activation factor deficiencies in man. Am J Clin Pathol 1983; 79: 405-13.
53. Rhee JS, Black M, Schubert U et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402.
54. Santoso S, Sachs UJ, Kroll H et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-91.
55. Scapini P, Nesi L, Morini M et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002; 168: 5798-804.
56. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 1143-51.
57. Schenkel AR, Mamdouh Z, Chen X et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143-50.
58. Sim BK. Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 1998; 2: 37-48.
59. Simon DI, Chen CP, Xu H et al. Platelet glycoprotein Iba is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
60. Simon DI, Rao NK, Xu H et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-94.
61. Simon DI, Wei Y, Zhang L et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-34.
62. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
63. Stewart M, Thiel M, Hogg N. Leukocyte integrins. Curr Opin Cell Biol 1995; 7: 690-6.
64. Vinante F, Marchi M, Rigo A et al. Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. Blood 1999; 94: 3169-77.
65. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP et al. High molecular weight kininogen binds to Mac1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem 1994; 269: 19307.
66. Waldmann R, Abraham JP, Rebuck JW et al. Fitzgerald factor: a hitherto unrecognised coagulation factor. Lancet 1975; 1: 949-51.
67. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to aIIbβ3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-93.
68. Zhang JC, Claffey K, Sakthivel R et al. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000; 14: 2589-600.